- Home
- BRW vs KMDA Comparison
BRW vs KMDA Comparison
Compare BRW & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRW
- KMDA
- Stock Information
- Founded
- BRW 1987
- KMDA 1990
- Country
- BRW United States
- KMDA Israel
- Employees
- BRW N/A
- KMDA N/A
- Industry
- BRW Trusts Except Educational Religious and Charitable
- KMDA Biotechnology: Pharmaceutical Preparations
- Sector
- BRW Finance
- KMDA Health Care
- Exchange
- BRW Nasdaq
- KMDA Nasdaq
- Market Cap
- BRW 334.3M
- KMDA 394.4M
- IPO Year
- BRW N/A
- KMDA N/A
- Fundamental
- Price
- BRW $7.86
- KMDA $7.05
- Analyst Decision
- BRW
- KMDA Strong Buy
- Analyst Count
- BRW 0
- KMDA 2
- Target Price
- BRW N/A
- KMDA $14.50
- AVG Volume (30 Days)
- BRW 222.1K
- KMDA 159.8K
- Earning Date
- BRW 01-01-0001
- KMDA 03-05-2025
- Dividend Yield
- BRW 15.59%
- KMDA N/A
- EPS Growth
- BRW N/A
- KMDA 124.29
- EPS
- BRW N/A
- KMDA 0.27
- Revenue
- BRW N/A
- KMDA $158,380,000.00
- Revenue This Year
- BRW N/A
- KMDA $15.37
- Revenue Next Year
- BRW N/A
- KMDA $8.58
- P/E Ratio
- BRW N/A
- KMDA $25.36
- Revenue Growth
- BRW N/A
- KMDA 4.52
- 52 Week Low
- BRW $7.15
- KMDA $4.74
- 52 Week High
- BRW $8.30
- KMDA $8.00
- Technical
- Relative Strength Index (RSI)
- BRW 62.37
- KMDA 50.80
- Support Level
- BRW $7.81
- KMDA $6.90
- Resistance Level
- BRW $7.96
- KMDA $7.56
- Average True Range (ATR)
- BRW 0.10
- KMDA 0.19
- MACD
- BRW 0.02
- KMDA -0.09
- Stochastic Oscillator
- BRW 90.91
- KMDA 15.95
About BRW Saba Capital Income & Opportunities Fund SBI
Saba Capital Income & Opportunities Fund t is a diversified, closed-end management investment company. It seeks to provide investors with a high level of current income, with a secondary goal of capital appreciation. It invests globally in debt and equity securities of public and private companies, which includes, investing in closed-end funds, public and private debt instruments, and other securities.
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.